1-16 of 16
Authors: Yalan Zhang
Journal Article
PATH-40. “DE NOVO REPLICATION REPAIR DEFICIENT GLIOBLASTOMA, IDH-WILDTYPE” IS A DISTINCT GLIOBLASTOMA SUBTYPE IN ADULTS THAT MAY BENEFIT FROM IMMUNE CHECKPOINT BLOCKADE Free
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v177, https://doi.org/10.1093/neuonc/noad179.0670
Published: 10 November 2023
Journal Article
PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma Free
Neuro-Oncology, Volume 25, Issue 11, November 2023, Pages 2074–2086, https://doi.org/10.1093/neuonc/noad105
Published: 15 June 2023
Journal Article
CTNI-09. DIFFUSE MIDLINE GLIOMA-ADAPTIVE COMBINATORY TRIAL (DMG-ACT): A COMBINATION PLATFORM TRIAL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii71–vii72, https://doi.org/10.1093/neuonc/noac209.275
Published: 14 November 2022
Journal Article
SURG-19. PROGNOSTIC VALIDATION OF A NEW CLASSIFICATION SYSTEM FOR EXTENT OF RESECTION IN GLIOBLASTOMA: A REPORT OF THE RANO RESECT GROUP Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii255, https://doi.org/10.1093/neuonc/noac209.985
Published: 14 November 2022
Journal Article
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group Open Access
Neuro-Oncology, Volume 25, Issue 5, May 2023, Pages 940–954, https://doi.org/10.1093/neuonc/noac193
Published: 12 August 2022
Journal Article
DIPG-31. Prognostic and predictive biomarkers of response in children and young adults with H3K27M-altered diffuse intrinsic pontine glioma: results from a multi-center, interventional clinical trial (PNOC003) Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i25, https://doi.org/10.1093/neuonc/noac079.088
Published: 03 June 2022
Journal Article
DIPG-09. Diffuse Midline Glioma-Adaptive Combinatory Trial (DMG-ACT): A biology-driven platform trial in pediatric and young adult patients with diffuse midline glioma Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i19, https://doi.org/10.1093/neuonc/noac079.066
Published: 03 June 2022
Journal Article
Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomes Open Access
Neuro-Oncology, Volume 24, Issue 10, October 2022, Pages 1749–1762, https://doi.org/10.1093/neuonc/noac089
Published: 08 April 2022
Journal Article
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications Free
Neuro-Oncology, Volume 24, Issue 9, September 2022, Pages 1471–1481, https://doi.org/10.1093/neuonc/noac064
Published: 14 March 2022
Journal Article
SURG-15. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED DIFFUSE LOW-GRADE GLIOMA Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii206, https://doi.org/10.1093/neuonc/noaa215.862
Published: 09 November 2020
Journal Article
SURG-18. THE IMPACT OF NEUROLOGIC IMPAIRMENTS ON THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION IN NEWLY DIAGNOSED IDH-WILD TYPE GLIOBLASTOMA Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii207, https://doi.org/10.1093/neuonc/noaa215.865
Published: 09 November 2020
Journal Article
PATH-30. CLINICAL AND GENETIC CHARACTERISTICS OF HISTONE H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IN ADULTS Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii170–ii171, https://doi.org/10.1093/neuonc/noaa215.711
Published: 09 November 2020
Journal Article
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence Free
Neuro-Oncology, Volume 22, Issue 11, November 2020, Pages 1580–1590, https://doi.org/10.1093/neuonc/noaa059
Published: 13 March 2020
Journal Article
GENE-35. MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED LGG AS A POTENTIAL BIOMARKER FOR TMZ-ASSOCIATED HYPERMUTATION AT RECURRENCE Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi105, https://doi.org/10.1093/neuonc/noz175.437
Published: 11 November 2019
Journal Article
RTHP-33. A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS ON SURVIVAL BASED ON TREATMENT PARADIGMS FOR PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMA Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi216–vi217, https://doi.org/10.1093/neuonc/noz175.904
Published: 11 November 2019
Journal Article
PATH-05. IMPLEMENTATION OF A TARGETED NEXT-GENERATION SEQUENCING PANEL FOR THE DIAGNOSIS AND PRECISION MEDICINE TREATMENT OF ADULT PATIENTS WITH WHO GRADE IV DIFFUSE GLIOMAS Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi158–vi159, https://doi.org/10.1093/neuonc/noy148.661
Published: 05 November 2018
